Rx Bill Concedes Devices Distinct From Drugs, Yet Carries Device Provision
This article was originally published in The Gray Sheet
Executive Summary
FDA would be required to submit a report identifying the "deficiencies" in device postmarket surveillance under a bill establishing an independent drug postmarket safety office